Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company, announced on Wednesday that it has dosed its first subject in its phase II study of Silmitasertib (CX-4945) in subjects with community-acquired pneumonia (CAP) associated with viral infection in Taiwan.
The trial is to assess if early medical intervention of Silmitasertib restrains the advancement of CAP by inhibiting the elevated cytokine release related with SARS-CoV-2 and Influenza viruses.
This phase II trial is headed by an inter-hospital team specialising in infectious diseases, with experience in conducting large-scale international clinical trials for various anti-viral new drugs. The study team includes five hospitals including National Taiwan University Hospital, National Taiwan University Cancer Center, Far Eastern Memorial Hospital, Tri-Service General Hospital and Taoyuan General Hospital, Ministry of Health and Welfare.
The product is a first-in-class small molecule drug that is aimed at the CK2 protein and acts as a CK2 inhibitor.
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI
Technavio predicts increase in global peptide therapeutics market size
GSK secures global rights to CureVac's mRNA vaccines in new licensing deal
Biophytis reports positive Phase 2/3 results for COVID-19 treatment at WCID
SCG Cell Therapy's SCG142 IND application receives US FDA approval
EDX Medical to distribute cResponse cancer assay in UK and Nordics
Scancell Holdings announces evaluation agreement with major biotechnology company
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
YS Biopharma repays USD40m loan facility
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib